After Hours Summary: CERT +23.3% and RXRX +22.4% on FDA plans to phase out animal testing; ARGX +8.7% higher on FDA approval
After Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: ULCC +2.2% (lowers guidance), THS +2.1% (guides, also implements operational efficiency strategies)
Companies trading higher in after hours in reaction to news: CERT +23.3% (FDA to phase out animal testing in certain therapies), RXRX +22.4% (FDA to phase out animal testing in certain therapies), ARGX +8.7% (FDA approves VYVGART Hytrulo Prefilled Syringe for Self-Injection), CRL +5.4% (FDA to phase out animal testing in certain therapies; stock sold off late Thurs but recovering after hrs), TARA +4% (to present interim analysis from Phase 2 trial of TARA-002), ALSN +3.8% (names new CFO), HOG +2.4% (exploring $1+ bln sale of its financing arm, according to Bloomberg), AGX +2.1% (increases share repurchase program to $150 mln), ARDX +1.2% (to present data from OPTIMIZE Study), RRC +0.8% (provides expectations for Q1 derivatives), AGNC +0.7% (announces Q1 data), EQT +0.5% (provides expectations for Q1 derivatives), MTW +0.2% (files an anti-dumping petition), FAST +0.2% (increases dividend)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: None
Companies trading lower in after hours in reaction to news: J -10.3% (receives $70 mln and right to receive AMTM shares), CNC -5.5% (awarded Nevada Medicaid contract), ARQT -3.3% (CFO to retire, names new CFO), ML -1.5% (stockholders approve acquisition), GES -0.5% (partnership with WHP Global), LLY -0.5% (provides outlook on Q1 IPR&D charges)